DM
Therapeutic Areas
NervGen Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NVG-291 | Spinal Cord Injury | Phase 1b/2a |
Leadership Team at NervGen Pharma
PB
Paul Brennan
President & Chief Executive Officer, Director
W(
William (Bill) Radvak
Executive Chairman
MK
Michael Kelly
Chief Financial Officer
MT
Matthew Thatcher
Chief Scientific Officer
AH
Allan Hindmarsh
VP, Pharmaceutical Sciences
MR
Michele Rusnak
VP, Regulatory & Quality Assurance
JR
John Ruffolo
Director
JA
John A. B. (JAB) Young
Director
JA
Jane A. Gross
Director
JS
Jerry Silver
Scientific Advisory Board Member